



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/627063/2021

European Medicines Agency decision P/0524/2021

of 3 December 2021

on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine / dolutegravir (Juluca), (EMA-001750-PIP01-15-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0524/2021

of 3 December 2021

on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine / dolutegravir (Juluca), (EMA-001750-PIP01-15-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0030/2016 issued on 29 January 2016, the decision P/0028/2017 issued on 10 February 2017, the decision P/0054/2019 issued on 11 February 2019, the decision P/0359/2020 issued on 9 September 2020 and the decision P/0209/2021 issued on 10 May 2021,

Having regard to the application submitted by ViiV Healthcare UK Limited on 12 July 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 October 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for rilpivirine / dolutegravir (Juluca), film-coated tablet, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to ViiV Healthcare UK Limited, 980 Great West Road, TW8 9GS - Brentford, Middlesex, United Kingdom.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/415533/2021
Amsterdam, 15 October 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001750-PIP01-15-M05

Scope of the application

Active substance(s):

Rilpivirine / dolutegravir

Invented name:

Juluca

Condition(s):

Treatment of human immunodeficiency virus (HIV-1) infection

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

ViiV Healthcare UK Limited

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, ViiV Healthcare UK Limited submitted to the European Medicines Agency on 12 July 2021 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0030/2016 issued on 29 January 2016, the decision P/0028/2017 issued on 10



February 2017, the decision P/0054/2019 issued on 11 February 2019, the decision P/0359/2020 issued on 9 September 2020 and the decision P/0209/2021 issued on 10 May 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 17 August 2021.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of human immunodeficiency virus (HIV-1) infection

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- film-coated tablet; oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of human immunodeficiency virus 1 (HIV-1) infection

2.1.1. Indication(s) targeted by the PIP

Treatment of human immunodeficiency virus 1 (HIV-1) infection

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years of age and weighing at least 25 kg to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Study 1 Study deleted in EMEA-001750-PIP01-15-M04.
Non-clinical studies	0	Not applicable
Clinical studies	2	Study 2 (201676) Single dose, crossover pivotal bioequivalence evaluation of up to 2 fixed dose combination tablets of dolutegravir/rilpivirine compared to the co-administered reference formulations TIVICAY (dolutegravir) 50mg and EDURANT (rilpivirine) 25mg in healthy male and female adult volunteers Study 3

		Multicentre, single-arm study to evaluate the pharmacokinetics, safety, tolerability and antiviral efficacy of switching to dual therapy, dolutegravir (DTG) plus rilpivirine (RPV), in anti-retroviral therapy (ART)-experienced HIV-1-infected children, from 6 to less than 12 years of age who are virologically suppressed on their current anti-retroviral (ARV) regimen
Extrapolation, modelling and simulation studies	2	Study 4 DTG paediatric PopPK model for determination of paediatric dose Study 5 RPV paediatric PopPK model for determination of paediatric dose
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2023.
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of human immunodeficiency virus (HIV-1) infection

Authorised indication(s):

- Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use